Brain, Vol. 122, No. 2, 191-197,
February 1999
© 1999 Oxford University Press
Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis
A longitudinal clinical and MRI study
1 Department of Clinical Neurology, The Radcliffe Infirmary and 2 British Biotech Pharmaceuticals Ltd, Oxford, UK
Correspondence to:
Dr J. Palace, Department of Clinical Neurology, The Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HG, UK
Metalloproteinases have been implicated in the pathogenesis of multiple sclerosis. We report longitudinal serum levels of gelatinase B and of the tissue inhibitors of matrix metalloproteinases (TIMP), TIMP-1 and TIMP-2, in 21 patients with relapsing multiple sclerosis. Patients had monthly clinical and gadolinium-enhanced MRI follow-up for 10 months. Longitudinal samples in nine healthy controls and cross-sectional samples from 12 patients with inflammatory CNS disease and 15 patients with other neurological diseases were used for comparison. Average serum gelatinase B, TIMP-1 and TIMP-2 levels were significantly higher in multiple sclerosis patients and those with other neurological diseases than in healthy controls. In the patients with multiple sclerosis, gelatinase B levels were significantly higher during clinical relapse compared with periods of clinical stability. Multiple sclerosis patients with high mean serum gelatinase B levels had significantly more T1-weighted gadolinium-enhancing MRI lesions than those with mean levels within the control range. TIMP-1 levels were not different during relapse and between relapses. There was a trend for TIMP-2 levels to be lower during relapse compared with non-relapse periods. For similar levels of serum gelatinase B, associated TIMP-1 levels were significantly lower and TIMP-2 levels significantly higher in multiple sclerosis patients compared with the inflammatory CNS control group. We propose that an abnormality in the inhibitory response to metalloproteinases may play an aetiological role in the chronicity of multiple sclerosis.
matrix metalloproteinases; multiple sclerosis; TIMP and MRI
EDSS = expanded disability status scale; ELISA = enzyme-linked immunosorbent assay; MMP = matrix metalloproteinase; TIMP = tissue inhibitor of matrix metalloproteinases
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Zivadinov, B. Weinstock-Guttman, K. Hashmi, N. Abdelrahman, M. Stosic, M. Dwyer, S. Hussein, J. Durfee, and M. Ramanathan Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis Neurology, August 18, 2009; 73(7): 504 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Fainardi, M Castellazzi, C Tamborino, A Trentini, M. Manfrinato, E Baldi, M. Tola, F Dallocchio, E Granieri, and T Bellini Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis Multiple Sclerosis, May 1, 2009; 15(5): 547 - 554. [Abstract] [PDF]
|
|
|
|
|
|
K. Rithidech, L Honikel, M Milazzo, D Madigan, R Troxell, and L. Krupp Protein expression profiles in pediatric multiple sclerosis: potential biomarkers Multiple Sclerosis, April 1, 2009; 15(4): 455 - 464. [Abstract] [PDF]
|
|
|
|
|
|
Y Benesova, A Vasku, H Novotna, J Litzman, P Stourac, M Beranek, Z Kadanka, and J Bednarik Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis Multiple Sclerosis, March 1, 2009; 15(3): 316 - 322. [Abstract] [PDF]
|
|
|
|
 |
|
 A. E. Cardona, M. Li, L. Liu, C. Savarin, and R. M. Ransohoff Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation J. Leukoc. Biol., September 1, 2008; 84(3): 587 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Minagar, J. S. Alexander, R. N. Schwendimann, R. E. Kelley, E. Gonzalez-Toledo, J. J. Jimenez, L. Mauro, W. Jy, and S. J. Smith Combination Therapy With Interferon Beta-1a and Doxycycline in Multiple Sclerosis: An Open-Label Trial Arch Neurol, February 1, 2008; 65(2): 199 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mannello, G.A.M. Tonti, and F. Canestrari The `never-ending story' of the influence of blood specimen collection methods affecting the concentration, the zymographic profile and the usefulness of matrix metalloproteinases and their tissue inhibitors in multiple sclerosis diagnosis/prognosis: a landmark for limiting the misuse of serum samples Multiple Sclerosis, June 1, 2007; 13(5): 687 - 690. [PDF]
|
|
|
|
|
|
S. Dhib-Jalbut Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis Neurology, May 29, 2007; 68(22_suppl_3): S13 - S21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Gran, N Tabibzadeh, A Martin, E S Ventura, J H Ware, G-X Zhang, J L Parr, A R Kennedy, and A M Rostami The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis Multiple Sclerosis, November 1, 2006; 12(6): 688 - 697. [Abstract] [PDF]
|
|
|
|
|
|
E Fainardi, M Castellazzi, T Bellini, M C Manfrinato, E Baldi, I Casetta, E Paolino, E Granieri, and F Dallocchio Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis Multiple Sclerosis, June 1, 2006; 12(3): 294 - 301. [Abstract] [PDF]
|
|
|
|
 |
|
 T Kanesaka, M Mori, T Hattori, T Oki, and S Kuwabara Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis J. Neurol. Neurosurg. Psychiatry, February 1, 2006; 77(2): 185 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Avolio, M Filippi, C Tortorella, M A Rocca, M Ruggieri, F Agosta, V Tomassini, C Pozzilli, S Stecchi, P Giaquinto, et al. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment Multiple Sclerosis, August 1, 2005; 11(4): 441 - 446. [Abstract] [PDF]
|
|
|
|
|
|
J Sastre-Garriga, M Comabella, L Brieva, A Rovira, M Tintore, and X Montalban Decreased MMP-9 production in primary progressive multiple sclerosis patients Multiple Sclerosis, August 1, 2004; 10(4): 376 - 380. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R. L.P. Lindberg, and D. Leppert Neutralizing antibodies against IFN-{beta} in multiple sclerosis: antagonization of IFN-{beta} mediated suppression of MMPs Brain, February 1, 2004; 127(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Minagar and J S. Alexander Blood-brain barrier disruption in multiple sclerosis Multiple Sclerosis, December 1, 2003; 9(6): 540 - 549. [Abstract] [PDF]
|
|
|
|
|
|
I. Nelissen, E. Martens, P. E. Van Den Steen, P. Proost, I. Ronsse, and G. Opdenakker Gelatinase B/matrix metalloproteinase-9 cleaves interferon-{beta} and is a target for immunotherapy Brain, June 1, 2003; 126(6): 1371 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Waubant, D. Goodkin, A. Bostrom, P. Bacchetti, J. Hietpas, R. Lindberg, and D. Leppert IFN{beta} lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS Neurology, January 14, 2003; 60(1): 52 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Seifert, B C Kieseier, S Ropele, S Strasser-Fuchs, F Quehenberger, F Fazekas, and H-P Hartung TACE mRNA expression in peripheral mononuclear cells precedes new lesions on MRI in multiple sclerosis Multiple Sclerosis, December 1, 2002; 8(6): 447 - 451. [Abstract] [PDF]
|
|
|
|
 |
|
 G. A. Rosenberg Matrix Metalloproteinases and Neuroinflammation in Multiple Sclerosis Neuroscientist, December 1, 2002; 8(6): 586 - 595. [Abstract] [PDF]
|
|
|
|
|
|
G M Liuzzi, M Trojano, M Fanelli, C Avolio, A Fasano, P Livrea, and P Riccio Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis Multiple Sclerosis, June 1, 2002; 8(3): 222 - 228. [Abstract] [PDF]
|
|
|
|
|
|
V. Brundula, N. B. Rewcastle, L. M. Metz, C. C. Bernard, and V. W. Yong Targeting leukocyte MMPs and transmigration: Minocycline as a potential therapy for multiple sclerosis Brain, June 1, 2002; 125(6): 1297 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. D'Souza, B. Mak, and M. A. Moscarello The Up-regulation of Stromelysin-1 (MMP-3) in a Spontaneously Demyelinating Transgenic Mouse Precedes Onset of Disease J. Biol. Chem., April 12, 2002; 277(16): 13589 - 13596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Nelissen, I. Ronsse, J. Van Damme, and G. Opdenakker Regulation of gelatinase B in human monocytic and endothelial cells by PECAM-1 ligation and its modulation by interferon-beta J. Leukoc. Biol., January 1, 2002; 71(1): 89 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. P. Lindberg, C. J. A. De Groot, L. Montagne, P. Freitag, P. van der Valk, L. Kappos, and D. Leppert The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis Brain, September 1, 2001; 124(9): 1743 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Han, Y. Sun, S. Scott, and D. Bleich Tissue Inhibitor of Metalloproteinase-1 Prevents Cytokine-Mediated Dysfunction and Cytotoxicity in Pancreatic Islets and {beta}-cells Diabetes, May 1, 2001; 50(5): 1047 - 1055. [Abstract] [Full Text]
|
|
|
|
|
|
B. C. Kieseier, C. Schneider, J. M. Clements, A. J. H. Gearing, R. Gold, K. V. Toyka, and H.-P. Hartung Expression of specific matrix metalloproteinases in inflammatory myopathies Brain, February 1, 2001; 124(2): 341 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Harkness, P. Adamson, J. D. Sussman, G. A. B. Davies-Jones, J. Greenwood, and M. N. Woodroofe Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium Brain, April 1, 2000; 123(4): 698 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Waubant, D. E. Goodkin, L. Gee, P. Bacchetti, R. Sloan, T. Stewart, P.-B. Andersson, G. Stabler, and K. Miller Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis Neurology, October 22, 1999; 53(7): 1397 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Kieseier, T. Seifert, G. Giovannoni, and H.-P. Hartung Matrix metalloproteinases in inflammatory demyelination: Targets for treatment Neurology, July 1, 1999; 53(1): 20 - 20. [Abstract] [Full Text]
|
|
|
|
|
|
G. Opdenakker Metalloproteinases and specific inhibitors in multiple sclerosis: from blood to brain or vice versa? Brain, February 1, 1999; 122(2): 181 - 182. [Full Text] [PDF]
|
|